Topiramate psychiatric

Eads LA, Kramer T, Wooten G. Use of topiramate as a mood stabilizer. Presented at the American Psychiatric Association Annual Meeting, Chicago, May 13-18, 2000. 

In a retrospective chart review, weight loss was assessed in 214 patients with psychiatric disorders taking topiramate (1128). Patients taking either lithium or valproate gained a mean (SD) of 6.3 (9.0) kg and 6.4 (9.0) kg respectively, whereas patients taking topiramate lost 1.2 (6.3) kg. Similar statistically significant results were found in the bone mass index. 

Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate an open-label, nonrandomized chart review. Clin Ther 2002 24(10) 1576-84. 

Because she had a history of psychiatric diseases and panic attacks, the relation of these symptoms to topiramate was doubtful. 

The prevalence of psychiatric adverse events in relation to topiramate has been studied in 431 consecutive patients (648). There were psychiatric adverse events in 103 patients (24%), including affective disorder in 46 (11%),... 

Topiramate has been associated with several psychiatric adverse events, such as nervousness, depression, behavioral problems, mood lability, and psychosis. Obsessive-compulsive disorder has also been reported (650). 

The authors discussed the hypothesis of a coincidental finding as well as the development of an alternative psychosis but finally attributed the patient s psychiatric disorder to topiramate. 

Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003 44 659-63. 

Kusumakar V, Yatham L, O Donovan C et al. Topiramate in rapid cycling bipolar woman. 152nd Annual Meeting of the American Psychiatric Association, Washington, DC,... 

Psychiatric A patient with migraine developed reversible, dose-related, auditory hallucinations during topiramate therapy [313 ]. 

Psychiatric A 58-year-old man with fronto-temporal lobar degeneration and associated overeating and binging behavior had resolution of his abnormal eating while taking topiramate 50 mg/day [168 ]. Appetite suppression, which has previously been associated with topiramate use, was in this case a useful side effect of the drug. 

---